Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options
Levi & Korsinsky, LLP alerts investors in Boston Scientific Corporation (NYSE: BSX) of a pending securities class action. Class Period: July 23, 2025 through February 3, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Boston Scientific Corporation. (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of the securities laws.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026. Boston Scientific describes itself as a “a global company that develops, manufactures, and markets medical devices used across various specialties.”
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
What a brutal six months it’s been for Boston Scientific. The stock has dropped 29% and now trades at $76.39, rattling many shareholders. This might have inv...
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500 price target to a lofty 7,800. This projection, released as the market moves through the
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Boston Scientific (NYSE:BSX) and the rest of the medical devices & supplies - diversified stocks fared in Q4.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered safety but lacked the high-octane growth of its specialized med-tech peers. That narrative is shifting rapidly. Today, February 24, 2026, marks a watershed moment for [...]
